WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Medicago
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
KYAN Therapeutics | September 24, 2020
KYAN Therapeutics, Inc. ("KYAN"), a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for novel selective Class II HDAC inhibitors. KYAN has already commenced preclinical development of the lead candidate, which has been designated as KYAN-001, with early positive results. In vitro and in vivo studies of KYAN-001 have shown high efficacy for Multiple Myeloma and Prostate ...
Cell and Gene Therapy
Tachyon Therapeutics Inc. | August 25, 2022
Tachyon Therapeutics, Inc. a private biotechnology company developing transformative cancer therapies against novel targets, today announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug application to develop TACH101 for the treatment of advanced solid tumors. "The approval of this IND marks a significant milestone for the Company, as TACH101 will be the first KDM4 inhibitor to enter clinical stage. ...
FN Media Group | May 08, 2020
The biotech boom is back. After its big breakthrough a few years ago, the biotech industry fell silent. Now, it is in the spotlight once again as smart money races in to back some once-in-a-generation breakthroughs. Mentioned in today's commentary includes: CRISPR Therapeutics AG (NASDAQ: CRSP), Sangamo Therapeutics, Inc. (NASDAQ: SGMO), Microsoft Corporation (NASDAQ: MSFT), International Business Machines Corporation (NYSE: IBM), Apple Inc. (NASDAQ: AAPL).From exciti...
MedTech
Ligand Pharmaceuticals | July 29, 2021
Landing AI announced today that it has entered into a software licensing deal with Ligand Pharmaceuticals Incorporated to integrate LandingLens into Ligand's OmniAb and xPloration antibody discovery platforms. LandingLens is a software platform that offers an end-to-end process for developing, experimenting and delivering AI-powered visual inspection solutions. The new AI-powered tools enhance Ligand's high-throughput single B cell screening accuracy and throughput in a wi...
Medical, Industry Outlook
Whitepaper
Medical
Video
Cell and Gene Therapy, Medical
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE